Commercial Momentum and Diagnostic Evidence Move Together

Novartis reported Q3 2026 Pluvicto net sales of $674 million, up 20% (nine-month sales up 42% to $1.967 billion), with the FDA and China’s NMPA both clearing Pluvicto across all stages of PSMA-positive metastatic prostate cancer. The same week, a 6,999-patient German cohort found PSMA PET/CT staging associated with significantly longer overall survival (HR 0.54), cancer-specific survival (HR 0.37), and time to biochemical recurrence (HR 0.51; all P<0.001), with the clearest benefit in high-risk patients treated with radiotherapy. Commercial momentum and real-world diagnostic evidence are moving in the same direction.

Novartis reported Q3 2026 Pluvicto net sales of $674 million, up 20% year over year, with nine-month sales up 42% to $1.967 billion. The quarter also brought FDA and China NMPA approvals of Pluvicto in combination with an androgen receptor pathway inhibitor, extending its label across all stages of PSMA-positive metastatic prostate cancer — from metastatic hormone-sensitive disease through castration-resistant disease. Novartis also signed an exclusive global licensing deal with BoomRay Pharmaceuticals for an undisclosed preclinical radioligand asset, and flagged radioligand therapy as one of three platforms it is prioritizing for new manufacturing capacity.

Precede Biosciences presented ESMO 2026 plasma epigenomic profiling data from 57 mCRPC patients treated with 177Lu-PSMA-617, including 17 with paired baseline-and-progression samples. Predicted PSMA expression declined in 11 of those 17 patients at progression, alongside declines in other therapeutic targets (TROP2, SEZ6, CEACAM5, DLL3) — early evidence that target-loss resistance is detectable noninvasively from a single 1 mL plasma draw, and a case for sequencing strategies that look beyond PSMA alone.

AdvanCell reported updated Phase I TheraPb data at ESMO 2026 showing 80% of patients had a PSA decline of at least 50% at the recommended doses of its lead-212 PSMA alpha therapy ADVC001, with median radiographic progression-free survival of 11.2 months and no new safety signals across 22 patients followed a median of 14.1 months.

Perspective Therapeutics presented updated interim data at ESMO 2026 for its lead-212 therapy VMT-alpha-NET in advanced SSTR2-expressing neuroendocrine tumors, reporting disease control rates of 89% and 95% across two dose cohorts, 72% progression-free survival at 18 months, and no dose-limiting toxicities.

Novartis’s Q3 2026 Pluvicto growth came alongside broader FDA and China NMPA approvals and a new radioligand-therapy licensing deal with BoomRay Pharmaceuticals — see Story of the Week for the full figures.

Telix shareholders will vote December 1, 2026 on its merger with Isotope Technologies Munich, which carries $1.65 billion in upfront consideration plus up to $700 million in contingent payments.

Telix’s isotope unit ARTMS now holds contracts for 50 QUANTM Irradiation Systems, expanding global capacity to produce the medical isotopes radiopharmaceutical programs depend on.